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controlled trials; and 3) previous pharmacoeconomic OAB
studies. Due to lack of variance for success rate in published
reports, sensitivity analyses used +/- 50%. RESULTS: Success
rates for the treatments were 35.6%(OxyIR), 23.0%(OxyER),
39.0%(OxyTD), 24.6%(TolIR), and 16.8%(TolER). Cost per
complete continence was lowest for OxyIR ($5777), followed by
OxyTD ($6189), TolIR ($8658), OxyER ($9121), and TolER
($11,850). OxyER, TolIR, and TolER were dominated by OxyIR
and OxyTD. Comparing OxyIR, use of OxyTD was an addi-
tional $9916 per person with complete continence. Sensitivity
analyses found that success rate was the key parameter driving
the analysis. When the success rate of OxyIR varied from 17.8%
to 53.4%, the ICER of OxyTD changed from $1462 to being
dominated. When the success rate of OxyTD varied from 19.5%
to 58.5%, the ICER of OxyTD changed from being dominated
to $1151. Sensitivity analyses of other model parameters were
found to not change the rank orders of treatments. CONCLU-
SION: The results of this study suggested OxyIR is the most 
cost-effective treatment for overactive bladder among various
preparations of oxybutynin and tolterodine. The second cost-
effective agent is OxyTD.
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OBJECTIVE: To evaluate the economic value of a pharmaceu-
tical product, Kremezin, in treating patients with chronic renal
failure (CRF) by estimating the amount of cost savings due to its
effect of delaying the onset of receiving dialysis treatments.
METHODS: The types of costs included were direct medical and
non-medical costs, and productivity loss costs. The information
about the effect of Kremezin was obtained from the results of
randomized controlled clinical trials. Cost information was
derived from administrative data for 20 hemodialysis and 20
peritoneal patients from one tertiary care hospital, and 20
hemodialysis patients from one free-standing dialysis center. Per-
capita cost savings resulting from Kremezin therapy were sepa-
rately estimated for the cases delaying the onset of hemodialysis
and the cases for peritoneal dialysis. By computing the weighted
average for the cases of hemodialysis and peritoneal dialsyis, the
expected per-capita cost savings of a patient with CRF was
obtained. Using the discount rate of 5%, future cost savings were
converted to the present value. Budget impact analysis was 
performed to estimate the expected national cost savings if 
Kremezin is administered to 25%, 50%, and 75% of the total
incident dialysis patients in 2004. RESULTS: Depending on the
effect of Kremezin in delaying the onset of dialysis treatments by
one, two, or four years, a patient with CRF could save costs by
1.8¢ 5.5, 1.6¢ 5.1 and 3.4¢ 10.6 million Korean Won (KW),
respectively from the perspectives of insurer, patient, and society.
Also, the national ﬁnancial impact of adopting Kremezin for
25%, 50%, and 75% of the total incident dialysis patients was
estimated as cost savings of about 61,511¢ 579,162 million KW
per year in Korea. CONCLUSION: The estimated amount of
cost savings resulting from treating CRF patients with Kremezin
conﬁrms that its effect of delaying the onset of dialysis treatments
has a considerable economic value.
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OBJECTIVE: To describe treatment utilization and associated
costs for women diagnosed with stress urinary incontinence in a
Medicaid population. METHODS: We utilized a pooled data-
base consisting of health care claims for women enrolled in 
Medicaid in one of four states. After identifying women with a
coded diagnosis consistent with stress urinary incontinence
(SUI), treatment utilization and costs were determined for the 12
months after the urinary incontinence diagnosis. RESULTS: Of
the 13,672 women with a diagnosis of SUI, average urinary
incontinence-related costs were approximately $800 in the 12-
month study period, accounting for less than 0.1% of total Med-
icaid spending. Approximately one-third of the SUI patients
received an anticholinergic medication in the study period,
though these medications are not indicated for SUI treatment. A
total of 13% of women underwent a surgery for SUI in the study
period, with sling procedures performed most commonly. Mean
UI-speciﬁc costs in the study period for the surgical and non-
surgical SUI patients were $3258 and $424 (p < 0.001) respec-
tively. CONCLUSIONS: While overall population estimates of
the prevalence of any stress urinary incontinence symptoms often
are high, diagnosis and treatment utilization in the Medicaid
population is low, and overall costs of SUI treatment in Medic-
aid currently are minimal. Further efforts to understand the
appropriate detection, diagnosis, and treatment of women with
SUI are needed.
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OBJECTIVES: This study assessed per patient direct medical
costs and indirect work loss of diagnosed interstitial cystitis
(“IC”) patients from an employer’s perspective. Treatment
pattern of IC was also assessed. METHODS: Patients under age
65 with at least one IC diagnosis (n = 749) were drawn from a
de-identiﬁed, administrative database of approximately two-
million beneﬁciaries that includes medical, drug, and disability
claims for 1999–2002. A 2 :1 matched non-IC control sample
was randomly selected based on matching demographic charac-
teristics (i.e. age, gender, region of residence). Annual costs and
comorbidities were compared between IC and the non-IC
samples descriptively. A multivariate two-part regression model
was applied to estimate IC excess medical costs and indirect
work loss costs while adjusting for observed patient demo-
graphics and comorbidities. All costs were adjusted to 2002 USD
using Consumer Price Index (“CPI”). Intent-to-treat approach
was adopted to proﬁle treatment patterns of IC. RESULTS: An
average IC patient had 130% higher direct medical costs ($3756)
and 80% higher indirect costs ($725) than a non-IC patient.
Compared with non-IC patients, IC patients had higher diag-
nostic prevalence of prostatitis (Relative Risk (“RR”) = 40.0, P
< 0.05), endometriosis (RR = 7.4, P < 0.05), vulvodynia (RR =
6.9, P < 0.05), chronic pelvic pain (RR = 5.8, P < 0.05), and
urinary tract infections (RR = 5.1, P < 0.05). IC patients were
also more likely to suffer from depression (RR = 2.8, P < 0.05)
